We performed full modeling analysis of 5-HT(1A)-[(18)F]MPPF interactions using the beta-microprobe (beta P) and a YAP-(S)PET scanner. Sixteen Wistar rats were used for beta P (n=5) and YAP-(S)PET (n=5) acquisitions and metabolite studies (n=6). Time-concentration curves were obtained in the hippocampus, raphe dorsalis, frontal cortex and cerebellum, using three injections of [(18)F]MPPF at different specific activities. B'(max) values were estimated from a two (2T-5k)- and three (3T-7k)-tissue-compartment model with beta P and YAP-(S)PET time-concentration curves. The simplified reference tissue model (SRTM) was used to estimate binding potential (BP(SRTM)) values from data obtained with the first injection and the cerebellum as the reference region. Overall, the 3T-7k model provided a better fit than the 2T-5k model, as evaluated from AIC criteria in all experiments. The rank order of receptor density (B'max) values was as follows: hippocampus>raphe approximately frontal cortex>cerebellum. Non-negligible specific binding was observed in the cerebellum (B'max (beta P)=1.5+/-0.9 pmol/ml). Significant correlations (p<0.001) between B'max and BP(SRTM) values were evident with both beta P (r=0.895) and YAP-(S)PET (r=0.695). The YAP-(S)PET system underestimated the [18F]MPPF binding levels in brain due to limited resolution (i.e. partial volume), but led to similar conclusions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuroimage.2008.02.062DOI Listing

Publication Analysis

Top Keywords

5-ht1a-[18f]mppf interactions
8
yap-spet scanner
8
beta yap-spet
8
time-concentration curves
8
b'max values
8
vivo quantification
4
quantification 5-ht1a-[18f]mppf
4
interactions rats
4
yap-spet
4
rats yap-spet
4

Similar Publications

Performance evaluation of a MIP for the MISPE-LC determination of p-[F]MPPF and a potential metabolite in human plasma.

J Pharm Biomed Anal

February 2020

University of Liège (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium. Electronic address:

Within the family of serotonin (5-HT) receptors, the 5-HT subtype is particularly interesting as it may be involved in various physiological processes or psychological disorders. The p-[F]MPPF, a highly selective 5-HT antagonist, is used for in vivo studies in human or animal by means of positron emission tomography (PET) [1]. In order to selectively extract p-[F]MPPF and its main metabolites from plasma, molecularly imprinted polymer (MIP) was prepared against these compounds by using the p-MPPF as template.

View Article and Find Full Text PDF

Psychiatric comorbidities are prevalent in patients with epilepsy and greatly contribute to the overall burden of disease. The availability of reliable biomarkers to diagnose epilepsy-associated comorbidities would allow for effective treatment and improved disease management. Due to their non-invasive nature, molecular imaging techniques such as positron emission tomography (PET) are ideal tools to measure pathologic changes.

View Article and Find Full Text PDF

Oxytocin (OT), a neuropeptide involved in affiliation has been shown to enhance social skills in patients with autism spectrum disorders (ASD). Nevertheless, OT improvements seem ephemeral. Animal research has demonstrated OT action on serotonin (5-HT), an interaction that we also found in the healthy human brain.

View Article and Find Full Text PDF

Rationale: There is accumulating evidence for a role of GABA receptors in depression. GABA receptors are heterodimers of GABA and GABA receptor subunits. The predominant GABA subunit isoforms are GABA and GABA.

View Article and Find Full Text PDF

Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals.

Neuropharmacology

October 2016

Lyon Neuroscience Research Center, Université Claude Bernard Lyon1, CNRS, INSERM, Lyon, France; Hospices Civils de Lyon, Lyon, France; CERMEP-Imaging Platform, Lyon, France. Electronic address:

PET imaging studies using 5-HT1A receptor radiotracers show a decreased density of this receptor in hippocampi of patients with Alzheimer's disease (AD) at advanced stages. However, current 5-HT1A receptor radiopharmaceuticals used in neuroimaging are antagonists, thought to bind to 5-HT1A receptors in different functional states (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!